Amarin Corp PLC Executive Compensation (FY25)
AMRN · Executive and director compensation, fiscal 2023 to 2025
The Amarin Corp PLC brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Data as of September 20, 2026Latest filing (8-K): May 15, 2026
14 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
$1,500Get the executive brief
192 figures on this page: 181 cited to the filing that reported them, 11 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Aaron Berg: $3,277,385 → $3,540,366 (8.0% higher)
Say-on-pay support: 71.1% → 51.9% (19.2 points lower)
CEO pay ratio: 21:1 → 11:1 (47.6% lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is Amarin Corp PLC's chief executive and what were they paid?
Aaron Berg, President and Chief Executive Officer, received $3,540,366 in total compensation for fiscal 2025. Berg's total was 8.0% higher than the $3,277,385 reported for fiscal 2024.
What was Amarin Corp PLC's say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 51.9% of votes cast for or against in favor at the meeting held May 13, 2026.
Which companies are in Amarin Corp PLC's peer group?
The disclosed peer group names Coherus BioSciences, Inc., Collegium Pharmaceutical, Inc., Esperion Therapeutics, Inc., Evolus, Inc. and Harrow, Inc., among others.
What is Amarin Corp PLC's chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 11:1, against median employee compensation of $326,639.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Aaron Berg President and Chief Executive Officer | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Steven Ketchum Executive Vice President, President of Research and Development and Chief Scientific Officer | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Jonathan Provoost Executive Vice President, Chief Legal & Compliance Officer and Secretary | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Aaron Berg President and Chief Executive Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Steven Ketchum Executive Vice President, President of Research and Development and Chief Scientific Officer | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Jonathan Provoost Executive Vice President, Chief Legal & Compliance Officer and Secretary | ◇ | — | — | — | ◇ | — | ◇ | ◇ |
Peter Fishman Senior Vice President, Chief Financial Officer | ◇ | ◇ | ◇ | — | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Aaron Berg President and Chief Executive Officer | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Steven Ketchum Executive Vice President, President of Research and Development and Chief Scientific Officer | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
David Keenan Executive Vice President, Chief Operating Officer | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Jonathan Provoost Executive Vice President, Chief Legal & Compliance Officer and Secretary | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Peter Fishman Senior Vice President, Chief Financial Officer | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Aaron D. Berg | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| David P. Keenan | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Jonathan N. Provoost | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Peter L. Fishman | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Steven B. Ketchum | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Jonathan Provoost | Option | ◇ | — | ◇ | 1/10/2035 |
| Option | ◇ | — | ◇ | 11/15/2033 | |
| Steven Ketchum | Option | ◇ | — | ◇ | 1/10/2035 |
| Option | ◇ | — | ◇ | 2/21/2033 | |
| Option | ◇ | — | ◇ | 2/4/2032 | |
| Option | ◇ | — | ◇ | 2/1/2034 | |
| David Keenan | Option | ◇ | — | ◇ | 1/10/2035 |
| Option | ◇ | — | ◇ | 2/1/2034 | |
| Option | ◇ | — | ◇ | 6/1/2032 | |
| Option | ◇ | — | ◇ | 2/21/2033 | |
| Peter Fishman | Option | ◇ | — | ◇ | 1/10/2035 |
| Aaron Berg | Option | ◇ | — | ◇ | 2/1/2034 |
| Option | ◇ | — | ◇ | 2/4/2032 | |
| Option | ◇ | — | ◇ | 2/21/2033 | |
| Option | ◇ | — | ◇ | 6/26/2035 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Odysseas Kostas Board chair | ◇ | — | — | — | — | — | ◇ |
Keith L. Horn | ◇ | — | — | — | — | — | ◇ |
Diane E. Sullivan | ◇ | — | — | — | — | — | ◇ |
Louis Sterling III | ◇ | — | — | — | — | — | ◇ |
Patrice Bonfiglio | ◇ | — | — | — | — | — | ◇ |
Paul Cohen | ◇ | — | — | — | — | — | ◇ |
Oliver O'Connor | ◇ | — | — | — | — | — | ◇ |
Michael Torok | ◇ | — | — | — | — | — | ◇ |
Mark DiPaolo | ◇ | — | — | — | — | — | ◇ |
Aaron D. Berg served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Coherus BioSciences, Inc. CHRS
- Collegium Pharmaceutical, Inc. COLL
- Esperion Therapeutics, Inc. ESPR
- Evolus, Inc. EOLS
- Harrow, Inc. HROW
- Heron Therapeutics, Inc. HRTX
- Innoviva, Inc. INVA
- Ironwood Pharmaceuticals, Inc. IRWD
- Karyopharm Therapeutics, Inc. KPTI
- MacroGenics, Inc. MGNX
- Puma Biotechnology, Inc. PBYI
- Revance Therapeutics Inc. RVNC
- Rigel Pharmaceuticals Inc. RIGL
- Travere Therapeutics, Inc. TVTX
- Vanda Pharmaceuticals Inc. VNDA
- Xeris Biopharma Holdings Inc. XERS
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | May 13, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | May 13, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | April 18, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | July 21, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | June 27, 2022 | = | ◇ | ◇ | ◇ |
| 2020 | June 14, 2021 | = | ◇ | ◇ | ◇ |
| 2019 | July 13, 2020 | = | ◇ | ◇ | ◇ |
| 2018 | May 20, 2019 | = | ◇ | ◇ | ◇ |
| 2017 | May 14, 2018 | = | ◇ | ◇ | ◇ |
| 2016 | May 15, 2017 | = | ◇ | ◇ | ◇ |
| 2015 | July 11, 2016 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
What this page does not include
Everything above is a fact Amarin Corp PLC disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Amarin Corp PLC sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceSay-on-pay responsiveness
Amarin Corp PLC recorded a low support level. The responsiveness analysis covers what the company said it would do, what it did, and how that compares with the companies that recovered their vote.
Responsiveness analysisAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
192 figures on this page: 181 cited to the filing that reported them, 11 calculated from figures it prints.
181 cited to the filing
11 calculated from the filing
Documents cited
- 0001193125-26-224771
- 0001193125-26-1514172025 Summary Compensation Table · Chief Executive Officer Pay Ratio · Grants of Plan-Based Awards Tables for the Fiscal Year Ended December 31, 2025 · Non-Employee Director Compensation · and 1 more section
- 0000950170-25-072817
- 0000950170-25-052674Summary Compensation Table
- 0000950170-24-046290Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000950170-24-0243532023 Summary Compensation Table
- 0001193125-23-192541Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-22-186302Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-21-190656Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-20-192691Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-19-155481Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-18-168093Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-17-175994Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-16-648264Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Amarin Corp PLC executive compensation, FY2023–FY2025.” https://intel.velarion.ai/comp/AMRN (accessed 2026).
Short form: data: Velarion
The Amarin Corp PLC brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
14 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Amarin Corp PLC and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers Amarin Corp PLC discloses
The companies named in AMRN's own disclosed peer group.
Coherus BioSciences, Inc.Collegium Pharmaceutical, Inc.Esperion Therapeutics, Inc.Evolus, Inc.Harrow, Inc.Heron Therapeutics, Inc.Innoviva, Inc.Ironwood Pharmaceuticals, Inc.Karyopharm Therapeutics, Inc.MacroGenics, Inc.Puma Biotechnology, Inc.Revance Therapeutics Inc.Rigel Pharmaceuticals Inc.Travere Therapeutics, Inc.Vanda Pharmaceuticals Inc.Xeris Biopharma Holdings Inc.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}